The field of cell therapy has experienced enormous growth, driven by advances in cellular engineering and expanding knowledge of immune cell biology. CRISPR-based approaches for precise gene modification and tumor targeting strategies involving antigen-specific receptors have improved therapeutic potencies, increased treatment specificities and reduced toxic side effects.  However, despite these strategic advances, challenges remain for safe and efficient delivery of molecules to primary cells. Traditional reliance on viral vectors has become problematic due to high manufacturing costs and regulatory concerns. In this presentation, we describe a safe and efficient alternative to viral delivery based on a clinically-validated electroporation platform. We’ll share data on introducing mRNA, DNA and RNPs into a variety of cell types, including T cells, NK cells and stem cells. We’ll also provide examples of electroporation-based cell therapy manufacturing strategies that are currently in the clinic, and we’ll describe a recently approved CRISPR-based therapy for treating hematological disorders.